David Sobek

Articles From This Author

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Jan 9, 2015 10:42 AM EST

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

Dec 18, 2014 9:35 AM EST

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug

Nov 19, 2014 11:17 AM EST

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

Nov 5, 2014 8:00 AM EST

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug

Oct 15, 2014 9:35 AM EDT

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Oct 2, 2014 9:21 AM EDT

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Sep 17, 2014 8:26 AM EDT

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report

Sep 10, 2014 9:36 AM EDT

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

Sep 3, 2014 6:30 AM EDT

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Aug 27, 2014 8:00 AM EDT

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Aug 21, 2014 8:59 AM EDT

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Aug 13, 2014 10:49 AM EDT

Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind

Jul 31, 2014 8:35 AM EDT

CTI Biopharma Posts Positive Myelofibrosis Study Results

Jul 16, 2014 9:03 AM EDT

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

Jul 9, 2014 10:14 AM EDT

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

Jun 26, 2014 10:23 AM EDT

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Jun 11, 2014 9:50 AM EDT

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Jun 2, 2014 7:45 AM EDT

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

May 28, 2014 8:08 PM EDT

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings

May 21, 2014 8:00 AM EDT

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

May 14, 2014 7:00 AM EDT

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

May 7, 2014 10:18 AM EDT

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Apr 16, 2014 8:00 AM EDT

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Apr 9, 2014 10:06 AM EDT

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Apr 2, 2014 8:00 AM EDT

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

Mar 25, 2014 10:22 AM EDT

CTI Biopharma Posts Positive Myelofibrosis Study Results

Feb 20, 2014 7:30 AM EST

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Feb 11, 2014 11:29 AM EST

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

Jan 30, 2014 12:06 PM EST

CTI Biopharma Posts Positive Myelofibrosis Study Results

Jan 23, 2014 8:00 AM EST

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

Jan 8, 2014 8:00 AM EST

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales

Dec 18, 2013 8:00 AM EST

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Dec 4, 2013 11:35 AM EST

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Nov 27, 2013 7:00 AM EST

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Nov 19, 2013 8:08 AM EST

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report

Nov 13, 2013 10:38 AM EST

Ampio's Eye Drug Approval Strategy Dealt Another Credibility Hit

Oct 30, 2013 11:26 AM EDT

AbbVie Deserves More Respect

Oct 16, 2013 7:00 AM EDT

Ampio's Eye Drug Approval Strategy Dealt Another Credibility Hit

Oct 9, 2013 12:51 PM EDT

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Oct 2, 2013 8:30 AM EDT

Galapagos Receives a Rousing Welcome on Its First Day of Trading

Sep 25, 2013 8:59 AM EDT

One Short Seller's Take On Arena's Slow Belviq Launch

Sep 19, 2013 8:30 AM EDT

Steve Rosenman Says Amarin Has Sticky Web Eyeballs!

Sep 12, 2013 8:19 AM EDT

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

Sep 5, 2013 8:00 AM EDT

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Aug 28, 2013 9:30 AM EDT

One Short Seller's Take On Arena's Slow Belviq Launch

Aug 20, 2013 9:59 AM EDT

One Short Seller's Take On Arena's Slow Belviq Launch

Aug 7, 2013 10:14 AM EDT

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

Jul 31, 2013 7:37 AM EDT

Steve Rosenman Says Amarin Has Sticky Web Eyeballs!

Jul 25, 2013 9:07 AM EDT

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

Jul 17, 2013 10:52 AM EDT

CLOSE

CLOSE

CLOSE

CLOSE